表紙
市場調査レポート

口腔用薄膜市場

Oral Thin Films Market, 2015 - 2025

発行 ROOTS ANALYSIS 商品コード 322756
出版日 ページ情報 英文 249 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.85円で換算しております。
Back to Top
口腔用薄膜市場 Oral Thin Films Market, 2015 - 2025
出版日: 2015年01月12日 ページ情報: 英文 249 Pages
概要

現在上市されている口腔用薄膜処方薬は10品目あり、2015年〜2016年にかけて6品目が上市されるものとみられています。こうした製品の54%が口腔経粘膜投与の薄膜となっています。

当レポートでは、口腔用薄膜市場の現状と将来動向、口腔経粘膜投与の長所と短所、口腔薄膜のアンメットニーズと市場の背景と課題、製品プロファイルおよび企業プロファイルなどをまとめています。

第1章 序論

第2章 エグゼクティブサマリー

第3章 口腔経粘膜ドラッグデリバリー

  • 本章の概要
  • 経口投与
  • 口腔経粘膜投与
  • 口腔経粘膜投与による機序
  • 口腔経粘膜投与の長所
  • 口腔経粘膜投与の短所
  • 舌下および頬用剤形

第4章 口腔用薄膜

  • 本章の概要
  • 口腔用薄膜の登場
  • 定義と分類
  • 組成/成分
  • 製造方法
  • 保存と包装

第5章 概要と市場の背景

  • 本章の概要
  • OTC製品
  • 技術および技術プロバイダー
  • 処方製品
  • 製造設備
  • 包装設備

第6章 製品プロファイル

  • 本章の概要
  • アドレナリン
  • アポモルヒネ
  • アリピプラゾール
  • ブプレノルフィン
  • ドネペジル
  • フェンタニル
  • インフルエンザワクチン
  • インスリン
  • レボドパ 他

第7章 市場予測

  • 本章の概要
  • 範囲と限界
  • 予測方法

第8章 SWOT分析

第9章 企業プロファイル

  • MonoSol Rx
  • tesa Labtec GmbH
  • IntelGenX
  • BioDelivery Sciences
  • Cynapsus Therapeutics
  • FFT Medical
  • Innoteq
  • Adhesives Research

第10章 結論

第11章 付録1:表データ

第12章 付録2:企業・組織リスト

図表

目次
Product Code: RA10031

Oral drug delivery technologies form an integral part of the pharmaceutical industry. From the conventional tablets / capsules to modern-day fast disintegrating and rapidly acting tablets / films, the market has come a long way. Lower bioavailability of oral solid drugs, inconvenience of administering injections, inaccurate dosing by liquid formulations have turned the focus of pharmaceutical companies to develop novel oral dosage forms that eliminate several known limitations. In addition, dysphagia, a common problem due to difficulty in swallowing in people of all ages, especially paediatric, geriatric, psychiatric, uncooperative and nauseated patients, has led to increase in demand of an alternative dosage form that provides rapid dissolution without the need of water and rapid onset of action when delivered through oral mucosa.

Oral thin films are able to meet most of these challenges. The concept isn't new and several over-the-counter oral thin films are readily available. Good acceptance from the users and an increasing demand of over-the-counter oral film products has led to the development of prescription drugs into oral thin films. These films not only offer a range of benefits to specific patient population segments but also provide a number of additional benefits to other stakeholders in the industry. The emerging area has gained attention from both established and start- up pharmaceutical firms.

Companies are utilizing their oral thin film technologies to develop different types of oral thin films (e.g. oral dispersible, sublingual, buccal). In addition to the drugs, several hormones and vaccines are also being formulated into oral thin films with the aim of providing improved patient compliance. Some of the key players in this area include MonoSol Rx, Applied Pharma Research/ Labtec GmbH, BioDelivery Sciences and NAL Pharma. Many companies are collaborating with these technology providers and utilizing oral thin films as a life cycle management tool for their branded drugs that have lost patent in other dosage forms.

There are not many prescription oral thin films currently available in the market; however, the pipeline holds a wider promise. Despite the uncertainties related to the development, approval and penetration rate, the market is likely to witness stable growth in the coming decade.

Synopsis:

The ‘Oral Thin Films’ market report provides a comprehensive analysis of the current state of the market and the likely future evolution over the next ten years. Starting with the basic introduction to the oral transmucosal route, its advantages and disadvantages, the report lays emphasis on the unmet needs fulfilled by oral thin films. Although oral thin films have been available in the forms of breath freshening strips, vitamin strips and other over-the-counter products for the past few decades, pharmaceutical companies have recently directed their focus towards formulating prescription products into oral thin films.

The study includes all prescription oral thin films, not necessarily delivered through oral mucosa. For these products, we have provided detailed profiles, underlying technologies being used to develop them and information on the key companies leading the efforts. We have also provided a detailed view on the key drivers behind the growth of this market, likely challenges and upcoming threats under the SWOT framework.

Many patients primarily paediatric, geriatric and dysphasia find it difficult to swallow traditional tablets and capsules. Moreover, some diseases require rapid onset of action. This is possible through injections; some patients, though, find it inconvenient and painful to administer injections. Oral thin films provide the best alternative dosage form for administering drug for such patients. It is important to highlight that not many prescription oral thin film products are commercially available yet. Several companies are developing innovative technologies to formulate oral thin films, which provide the advantage of rapid dissolution without the need of water and rapid onset of action when delivered through mucosa.

Given the specific advantages offered by these films and their ability to overcome the current unmet needs, the future holds significant potential. In fact, one of the primary objectives of this report is to estimate size of this future promise offered by marketed oral thin films and those currently under development. We have identified the sales potential of various oral thin films for the period 2015 - 2025. Owing to the uncertain nature of this market, we have presented three scenarios for our market forecast; these scenarios represent different growth tracks of the industry likely to be influenced by variable adoption, pricing and the evolving competitive landscape.

Research Methodology

Most of the data presented in this report has been gathered by secondary research. For specific studies, we also conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will shape up across different regions and drug segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Other analysts' opinion reports

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Example Highlights

  • 1. There are 10 prescription oral thin films currently in the market. In addition, there are 29 such films which are currently in different stages of clinical / pre-clinical development. Of these, six products are expected to get launched in 2015 / 2016 in their respective geographies.
  • 2. Approximately 54% of these products are oral transmucosal thin films. These films can be administered through sublingual, buccal or oral mucosal route, providing advantage of rapid onset of action.
  • 3. A number of these products (approx. 38%) are based on either MonoSol’s PharmFilm technology or Applied Pharma Research / Labtec’s RapidFilm technology. In addition to these two, there are over 10 other proprietary oral thin film technologies; some of these are currently being utilized for formulating over-the-counter products.
  • 4. Some start-ups such as FFT Medical and Cynapsus Therapeutics have also recently emerged; these new companies are coming up with their oral transmucosal thin film products and are likely to foster more innovation in the coming few years.
  • 5. Of all the marketed products, Suboxone film has found a strong acceptance in a short span of time; other marketed products such as Breakyl, Onsolis and Zuplenz are also gaining ground in different geographies. Overall, as more products get launched, we expect the market to sustain the growth momentum.

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research. The summary offers a high level view on the likely evolution of oral thin films market.

Chapter 3 provides a general introduction to the oral transmucosal route, covering details on different oral mucosal sites including the most common sublingual and buccal. The chapter also talks about the various sublingual and buccal dosage forms available in the market.

Chapter 4 provides an introduction to oral thin films, their features, advantages and disadvantages. The chapter provides details on the composition, manufacturing methods, storage and packaging of the oral thin films.

Chapter 5 highlights various developments which have taken place in the field of oral thin films. We have looked at prescription oral thin films (both marketed and in different stages of development) and some of the most common over-the-counter oral thin films. The chapter also lists the various technologies which are being used by pharmaceutical companies for developing oral thin films.

Chapter 6 provides detailed profiles on various drugs and vaccines being targeted for formulation into oral thin films. Starting with the introduction, these profiles cover historical developments of specific drugs / vaccines in other dosage forms, target population, historical sales and recent developments.

Chapter 7 looks at the future state of oral thin films market till 2025. It highlights the leading oral thin film products which are likely to drive the upcoming growth and the relative market size of oral thin films in terms of sales.

Chapter 8 provides the SWOT analysis of oral thin films market giving strategic insights to the major factors that are likely to contribute to future growth while also highlighting the weakness and threats that can negatively impact the evolution.

Chapter 9 includes profiles of the key companies active in this market. It covers detailed information on the technology provided by the each company, financial performance, marketed / pipeline products, recent developments, collaborations and future growth plans.

Chapter 10 summarizes the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in the previous chapters.

Chapter 11 is an appendix, which provides tabulated data and numbers for all the figures presented in the report.

Chapter 12 is an appendix, which provides a list of companies and organizations mentioned in this report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. ORAL TRANSMUCOSAL DRUG DELIVERY

  • 3.1. Chapter Overview
  • 3.2. Oral Route
  • 3.3. Oral Transmucosal Route
    • 3.3.1. Sublingual Administration
    • 3.3.2. Buccal Administration
    • 3.3.3. Local Administration
  • 3.4. Mechanism Involved in Oral Transmucosal Drug Administration
  • 3.5. Advantages of Oral Transmucosal Drug administration
  • 3.6. Disadvantages of Oral Transmucosal Drug Administration
  • 3.7. Sublingual and Buccal Dosage Forms
    • 3.7.1. Sublingual Tablet Forms
    • 3.7.2. Buccal Tablet Forms
    • 3.7.3. Sublingual and Buccal Oral Thin Films
    • 3.7.4. Sublingual Immunotherapy (SLIT) / Sublingual Drops
    • 3.7.5. Buccal Bioadhesive Patches

4. ORAL THIN FILMS

  • 4.1. Chapter Overview
  • 4.2. Emergence of Oral Thin Films
  • 4.3. Oral Thin Films: Definition and Classification
    • 4.3.1. Classification by Absorption Site
    • 4.3.2. Classification by Properties / Wafer Type
    • 4.3.3. Mechanism of Action
    • 4.3.4. Features of an Ideal Oral Thin Film
    • 4.3.5. Ideal Characteristics of Suitable Drug Candidates
  • 4.4. Composition / Ingredients of Oral Thin Films
    • 4.4.1. Active Pharmaceutical Ingredients
    • 4.4.2. Water Soluble Polymers
    • 4.4.3. Plasticizers
    • 4.4.4. Saliva Stimulating Agents
    • 4.4.5. Sweetening and Flavouring Agents
    • 4.4.6. Surfactants and Colouring Agents
    • 4.4.7. Permeation Enhancers
    • 4.4.8. Stabilizing and Thickening Agents
  • 4.5. Manufacturing Methods for Oral Thin Films
    • 4.5.1. Solvent Casting Method
    • 4.5.2. Semisolid Casting Method
    • 4.5.3. Hot Melt Extrusion Method
    • 4.5.4. Solid Dispersion Extrusion Method
    • 4.5.5. Rolling Method
  • 4.6. Storage and Packaging of Oral Thin Films

5. OVERVIEW AND MARKET BACKGROUND

  • 5.1. Chapter Overview
  • 5.2. Over-the-Counter Oral Thin Film Products
  • 5.3. Technology and Technology Providers
  • 5.4. Prescription Oral Thin Film Products
    • 5.4.1. Distribution by Type of Oral Thin Film
    • 5.4.2. Distribution by Type of Product
    • 5.4.3. Distribution by Type of Technology
    • 5.4.4. Distribution by Development Status
  • 5.5. Manufacturing Facilities for Oral Thin Films
  • 5.6. Packaging Facilities for Oral Thin Films

6. PRODUCT PROFILES

  • 6.1. Chapter Overview
  • 6.2. Adrenalin
    • 6.2.1. Overview
    • 6.2.2. Development History
    • 6.2.3. Dosage Forms of Adrenalin
    • 6.2.4. Target Population
    • 6.2.5. Adrenalin Sales
    • 6.2.6. Oral Thin Film Formulation of Adrenalin
      • 6.2.6.1. Adrenalin Oral Transmucosal Thin Film
  • 6.3. Apomorphine
    • 6.3.1. Overview
    • 6.3.2. Development History
    • 6.3.3. Dosage Forms of Apomorphine
    • 6.3.4. Oral Thin Film Formulation of Apomorphine
      • 6.3.4.1. APL-130277
    • 6.3.5. Target Population
    • 6.3.6. Apomorphine Sales
  • 6.4. Aripiprazole
    • 6.4.1. Overview
    • 6.4.2. Development History
    • 6.4.3. Dosage Forms of Aripiprazole
    • 6.4.4. Target Population
    • 6.4.5. Aripiprazole Sales
    • 6.4.6. Aripiprazole RapidFilm
  • 6.5. Buprenorphine (Single / Combination)
    • 6.5.1. Overview
    • 6.5.2. Development History
    • 6.5.3. Dosage Forms of Buprenorphine (Single / Combination)
    • 6.5.4. Target Population
    • 6.5.5. Oral Thin Formulation of Buprenorphine (Single / Combination)
      • 6.5.5.1. Suboxone Film (Buprenorphine and Naloxone)
      • 6.5.5.2. Bunavail (Buprenorphine and Naloxone)
      • 6.5.5.3. BEMA Buprenorphine
    • 6.5.6. Buprenorphine Sales
  • 6.6. Donepezil
    • 6.6.1. Overview
    • 6.6.2. Development History
    • 6.6.3. Dosage Forms of Donepezil
    • 6.6.4. Target Population
    • 6.6.5. Oral Thin Film Formulation of Donepezil
      • 6.6.5.1. Donepezil RapidFilm
      • 6.6.5.2. NAL8817
    • 6.6.6. Donepezil Sales
  • 6.7. Fentanyl
    • 6.7.1. Overview
    • 6.7.2. Development History
    • 6.7.3. Dosage Forms of Fentanyl
    • 6.7.4. Oral Thin Film Formulation of Fentanyl
      • 6.7.4.1. Onsolis
      • 6.7.4.2. Breakyl
      • 6.7.4.3. Painkyl
      • 6.7.4.4. Fastanix/ NAL1239
    • 6.7.5. Fentanyl Sales
  • 6.8. Flu/Influenza Vaccine
    • 6.8.1. Overview
    • 6.8.2. Dosage Forms of Flu/Influenza Vaccine
    • 6.8.3. Target Population
    • 6.8.4. Flu/Influenza Vaccine Sales
    • 6.8.5. Oral Thin Film Formulation of Flu/Influenza Vaccine
  • 6.9. Insulin
    • 6.9.1. Overview
    • 6.9.2. Dosage Forms of Insulin
    • 6.9.3. Target Population
    • 6.9.4. Insulin Sales
    • 6.9.5. Oral Thin Film Formulation of Insulin
  • 6.9.5.1. MidaForm Insulin PharmFilm
  • 6.10. Levodopa
    • 6.10.1. Overview
    • 6.10.2. Development History
    • 6.10.3. Dosage Forms of Levodopa / Carbidopa
    • 6.10.4. Target Population
    • 6.10.5. Levodopa/ Carbidopa Sales
    • 6.10.6. Oral Thin Film Formulation of Levodopa
  • 6.10.6.1. Levodopa Oral Transmucosal Thin Film
  • 6.11. Montelukast Sodium
    • 6.11.1. Overview
    • 6.11.2. Development History
    • 6.11.3. Dosage Forms of Montelukast Sodium
    • 6.11.4. Target Population
    • 6.11.5. Montelukast Sodium Sales
    • 6.11.6. Oral Thin Film Formulation of Montelukast Sodium
      • 6.11.6.1. Montelukast Sodium PharmFilm
      • 6.11.6.2. NAL6336
  • 6.12. Olanzapine
    • 6.12.1. Overview
    • 6.12.2. Development History
    • 6.12.3. Dosage Forms of Olanzapine
    • 6.12.4. Target Population
    • 6.12.5. Olanzapine RapidFilm
    • 6.12.6. Olanzapine Sales
  • 6.13. Ondansetron
    • 6.13.1. Overview
    • 6.13.2. Development History
    • 6.13.3. Target Population
    • 6.13.4. Oral Thin Film Formulation of Ondansetron
      • 6.13.4.1. Zuplenz
      • 6.13.4.2. Setofilm
      • 6.13.4.3. Ondissolve
    • 6.13.5. Ondansetron Sales
  • 6.14. Penicillin G
    • 6.14.1. Overview
    • 6.14.2. Dosage Forms of Penicillin G
    • 6.14.3. Penicillin G Sales
    • 6.14.4. Oral Thin Film Formulation of Penicillin G
      • 6.14.4.1. Penicillin G Oral Transmucosal Thin Film
  • 6.15. Rizatriptan
    • 6.15.1. Overview
    • 6.15.2. Development History
    • 6.15.3. Dosage Forms of Rizatriptan
    • 6.15.4. Target Population
    • 6.15.5. Rizatriptan Sales
    • 6.15.6. Oral Thin Formulation of Rizatriptan
      • 6.15.6.1. MSRX-202
      • 6.15.6.2. Rizaport
      • 6.15.6.3. NAL1606
  • 6.16. Rotavirus Vaccine
    • 6.16.1. Overview
    • 6.16.2. Development History
    • 6.16.3. Dosage Forms of Rotavirus Vaccine
    • 6.16.4. Target Population
    • 6.16.5. Rotavirus Vaccine Sales
    • 6.16.6. Oral Thin Film Formulation of Rotavirus Vaccine
      • 6.16.6.1. Aridis Pharmaceuticals
      • 6.16.6.2. Hilleman Laboratories
  • 6.17. Testosterone
    • 6.17.1. Overview
    • 6.17.2. Dosage Forms of Testosterone
    • 6.17.3. Target Population
    • 6.17.4. Testosterone Sales
    • 6.17.5. Oral Thin Film Formulation of Testosterone
      • 6.17.5.1. MSRX-110
  • 6.18. Zolmitriptan
    • 6.18.1. Overview
    • 6.18.2. Development History
    • 6.18.3. Dosage Forms of Zolmitriptan
    • 6.18.4. Target Population
    • 6.18.5. Oral Thin Film Formulation of Zolmitriptan
      • 6.18.5.1. Zolmitriptan RapidFilm
    • 6.18.6. Zolmitriptan Sales

7. MARKET FORECAST

  • 7.1. Chapter Overview
  • 7.2. Scope and Limitations
  • 7.3. Forecast Methodology
  • 7.4. Overall Oral Thin Films Market, 2015-2025
  • 7.5. Buprenorphine and Naloxone:Suboxone film (MonoSol Rx) and Bunavail (BioDelivery Sciences)
    • 7.5.1. Suboxone film and Bunavail Sales Forecast: Short-Mid Term, 2015-2020
    • 7.5.2. Suboxone film and Bunavail Sales Forecast: Long Term, 2020-2025
  • 7.6. Fentanyl (BioDelivery Sciences): Onsolis (US), Breakyl (EU) and Painkyl (Canada)
    • 7.6.1. Fentanyl Oral Thin Film Sales Forecast: Short-Mid Term, 2015-2020
    • 7.6.2. Fentanyl Oral Thin Film Sales Forecast: Long Term, 2020-2025
  • 7.7. Ondansetron: Zuplenz (MonoSol Rx), Setofilm (Applied Pharma Research and Labtec) and Ondissolve (Applied Pharma Research and Labtec)
    • 7.7.1. Ondansetron Oral Thin Film Sales Forecast: Short-Mid Term, 2015-2020
    • 7.7.2. Ondansetron Oral Thin Film Sales Forecast: Long Term, 2020-2025
  • 7.8. Olanzapine: Olanzapine RapidFilm (Applied Pharma Research and Labtec)
    • 7.8.1. Olanzapine RapidFilm Sales Forecast: Short-Mid Term, 2015-2020
    • 7.8.2. Olanzapine RapidFilm Sales Forecast: Long Term, 2020-2025
  • 7.9. Donepezil: Donepezil RapidFilm (Applied Pharma Research and Labtec)
    • 7.9.1. Donepezil RapidFilm Sales Forecast: Short-Mid Term, 2015-2020
    • 7.9.2. Donepezil RapidFilm Sales Forecast: Long Term, 2020-2025
  • 7.10. Zolmitriptan: Zolmitriptan RapidFilm (Applied Pharma Research and Labtec)
    • 7.10.1. Zolmitriptan RapidFilm Sales Forecast: Short-Mid Term, 2015-2020
    • 7.10.2. Zolmitriptan RapidFilm Sales Forecast: Long Term, 2020-2025
  • 7.11. Rizatriptan: Rizaport (IntelGenX)
    • 7.11.1. Rizaport Sales Forecast: Short-Mid Term, 2016-2020
    • 7.11.2. Rizaport Sales Forecast: Long Term, 2020-2025
  • 7.12. Buprenorphine:BEMA Buprenorphine (BioDelivery Sciences)
    • 7.12.1. BEMA Buprenorphine Sales Forecast: Short-Mid Term, 2016-2020
    • 7.12.2. BEMA Buprenorphine Sales Forecast: Long Term, 2020-2025
  • 7.13. Montelukast Sodium: Montelukast Sodium PharmFilm (MonoSol Rx)
    • 7.13.1. Montelukast Sodium PharmFilm Sales Forecast: Short-Mid Term, 2016-2020
    • 7.13.2. Montelukast Sodium PharmFilm Sales Forecast: Long Term, 2020-2025

8. SWOT ANALYSIS

9. COMPANY PROFILES

  • 9.1. MonoSol Rx
  • 9.2. tesa Labtec GmbH
  • 9.3. IntelGenX
  • 9.4. BioDelivery Sciences
  • 9.5. Cynapsus Therapeutics
  • 9.6. FFT Medical
  • 9.7. Innoteq
  • 9.8. Adhesives Research

10. CONCLUSION

  • 10.1. Oral Thin Films: Significant Advantages and Major Drivers
  • 10.2. Emergence of New Technologies
  • 10.3. Market is Still Emerging; Launch of New Products Will Sustain the Momentum
  • 10.4. Overall Opportunity is Big
  • 10.5. Concluding Remarks

11. APPENDIX 1: TABULATED DATA

12. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures:

  • Figure 4.1: Classification by Absorption Site
  • Figure 5.1: Oral Thin Films: Distribution by Type
  • Figure 5.2: Oral Transmucosal Thin Films: Distribution by Absorption Site
  • Figure 5.3: Oral Thin Films: Distribution by Type of Product
  • Figure 5.4: Oral Thin Films: Distribution by Type of Technology
  • Figure 5.5: Oral Thin Films: Distribution by Development Status
  • Figure 6.1: Total Adrenalin Sales (USD Million)
  • Figure 6.2: Total Apomorphine Hydrochloride Sales (USD Million)
  • Figure 6.3: Total Aripiprazole Sales (USD Million)
  • Figure 6.4: Total Abilify Sales (USD Million)
  • Figure 6.5: Historical Development of Buprenorphine (Single / Combination)
  • Figure 6.6: Opioid User Composition of Regions Outside the US (Million)
  • Figure 6.7: Total Suboxone Film Sales (USD Million)
  • Figure 6.8: Suboxone Film: Sales and Market Share in the US (USD Billion)
  • Figure 6.9: Prevalence of Alzheimer’s Disease in the US: Distribution by Age
  • Figure 6.10: Total Donepezil Hydrochloride Sales (USD Million)
  • Figure 6.11: Aricept Sales by Eisai (JPY Billion)
  • Figure 6.12: Aricept Sales by Pfizer (USD Million)
  • Figure 6.13: Total Fentanyl Sales (USD Million)
  • Figure 6.14: Total Fentanyl Citrate Sales (USD Million)
  • Figure 6.15: Total Fentanyl Transdermal System Sales (USD Million)
  • Figure 6.16: Total Influenza Vaccine Sales (USD Million)
  • Figure 6.17: Total Levodopa / Carbidopa Sales (USD Million)
  • Figure 6.18: Total Montelukast Sodium Sales (USD Million)
  • Figure 6.19: Total Singulair Sales (USD Million)
  • Figure 6.20: Total Olanzapine Sales (USD Million)
  • Figure 6.21: Total Zyprexa Sales (USD Million)
  • Figure 6.22: Historical Development of Ondansetron
  • Figure 6.23: Total Penicillin G Benzathine Sales (USD Million)
  • Figure 6.24: Total Penicillin G Potassium Sales (USD Million)
  • Figure 6.25: Total Rizatriptan Benzoate Sales (USD Million)
  • Figure 6.26: Total Maxalt Sales (USD Million)
  • Figure 6.27: Total Rotavirus Vaccine Sales (USD Million)
  • Figure 6.28: Total Zolmitriptan Sales (USD Million)
  • Figure 6.29: Total Zomig Sales (USD Million)
  • Figure 7.1: Overall Oral Thin Films Market (USD Million), 2015-2025 (Base Scenario)
  • Figure 7.2: Suboxone film and Bunavail Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Base Scenario)
  • Figure 7.3: Suboxone film and Bunavail Sales Forecast (USD Million): Long Term, 2020-2025 (Base Scenario)
  • Figure 7.4: Fentanyl Oral Thin Film Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Base Scenario)
  • Figure 7.5: Fentanyl Oral Thin Film Sales Forecast (USD Million): Long Term, 2020-2025 (Base Scenario)
  • Figure 7.6: Ondansetron Oral Thin Film Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Base Scenario)
  • Figure 7.7: Ondansetron Oral Thin Film Sales Forecast (USD Million): Long Term, 2020-2025 (Base Scenario)
  • Figure 7.8: Olanzapine RapidFilm Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Base Scenario)
  • Figure 7.9: Olanzapine RapidFilm Sales Forecast (USD Million): Long Term, 2020-2025 (Base Scenario)
  • Figure 7.10: Donepezil RapidFilm Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Base Scenario)
  • Figure 7.11: Donepezil RapidFilm Sales Forecast (USD Million): Long Term, 2020-2025 (Base Scenario)
  • Figure 7.12: Zolmitriptan RapidFilm Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Base Scenario)
  • Figure 7.13: Zolmitriptan RapidFilm Sales Forecast (USD Million): Long Term, 2020-2025 (Base Scenario)
  • Figure 7.14: Rizaport Sales Forecast (USD Million): Short-Mid Term 2016-2020 (Base Scenario)
  • Figure 7.15: Rizaport Sales Forecast (USD Million): Long Term, 2020-2025 (Base Scenario)
  • Figure 7.16: BEMA Buprenorphine Sales Forecast (USD Million): Short-Mid Term 2016-2020 (Base Scenario)
  • Figure 7.17: BEMA Buprenorphine Sales Forecast (USD Million): Long Term, 2020-2025 (Base Scenario)
  • Figure 7.18: Montelukast Sodium PharmFilm Sales Forecast (USD Million): Short-Mid Term 2016-2020 (Base Scenario)
  • Figure 7.19: Montelukast Sodium PharmFilm Sales Forecast (USD Million): Long Term, 2020-2025 (Base Scenario)
  • Figure 9.1: IntelGenX Revenues, 2007-2013(USD Million)
  • Figure 9.2: BioDelivery Sciences Revenues, 2009-2013 (USD Million)
  • Figure 10.1: Oral Thin Films Market (USD Million): 2015, 2020, 2025

List of Tables:

  • Table 4.1: Classification by Properties/Wafer Type
  • Table 4.2: Composition of Oral Thin Films
  • Table 5.1: Over-the-Counter Oral Thin Films: Marketed and Pipeline Products
  • Table 5.2: Oral Thin Film Technologies
  • Table 5.3: Prescription Oral Thin Films: Marketed and Pipeline Products
  • Table 5.4: Manufacturing Facilities for Oral Thin Films
  • Table 5.5: Companies Offering Packaging Facilities for Oral Thin Films
  • Table 6.1: Active Ingredients Formulated in Oral Thin Films
  • Table 6.2: Adrenalin Self Administering Delivery Systems
  • Table 6.3: Apomorphine Brand Names
  • Table 6.4: APL-130277 Phase II Results
  • Table 6.5: Abilify: Approval History
  • Table 6.6: Aripiprazole Dosage Forms
  • Table 6.7: Buprenorphine: Pharmacokinetics Characteristics
  • Table 6.8: Buprenorphine Dosage Forms
  • Table 6.9: Comparison between Buprenorphine Transmucosal Dosage Forms
  • Table 6.10: Brand Names of Buprenorphine (Single / Combination) Thin Films
  • Table 6.11: BEMA Buprenorphine: Completed Phase III Efficacy Studies
  • Table 6.12: Donepezil Dosage Forms
  • Table 6.13: Fentanyl Dosage Forms
  • Table 6.14: Comparison of Various Fentanyl Transmucosal Dosage Forms
  • Table 6.15: Oral Thin Film Fentanyl Brands
  • Table 6.16: Levodopa / Carbidopa Dosage Forms
  • Table 6.17: Montelukast Sodium Dosage Forms
  • Table 6.18: Olanzapine Dosage Forms
  • Table 6.19: Brand Names of Ondansetron Oral Thin Films
  • Table 6.20: Penicillin G: Derivatives and Dosage Forms
  • Table 6.21: Rizatriptan Dosage Forms
  • Table 6.22: Testosterone Dosage Forms
  • Table 6.23: Zolmitriptan Dosage Forms
  • Table 7.1: Oral Thin Film Based Products: Market Availability/Expected Launch Year
  • Table 8.1: SWOT Analysis
  • Table 8.2: Drugs that have Lost / will Lose Patent in 2014, 2015, 2016
  • Table 9.1: MonoSol Rx Product Portfolio
  • Table 9.2: Labtec Oral Dispersible Film Product Portfolio
  • Table 9.3: IntelGenX Product Portfolio
  • Table 9.4: BioDelivery Sciences Product Portfolio
  • Table 9.5: FFT Medical Product Portfolio
  • Table 11.1: Oral Thin Films: Distribution by Type
  • Table 11.2: Oral Transmucosal Thin Films: Distribution by Absorption Site
  • Table 11.3: Oral Thin Films: Distribution by Type of Product
  • Table 11.4: Oral Thin Films: Distribution by Type of Technology
  • Table 11.5: Oral Thin Films: Distribution by Development Status
  • Table 11.6: Total Adrenalin Sales (USD Million)
  • Table 11.7: Total Apomorphine Hydrochloride Sales (USD Million)
  • Table 11.8: Total Aripiprazole Sales (USD Million)
  • Table 11.9: Total Abilify Sales (USD Million)
  • Table 11.10: Opioid User Composition of Regions Outside the US (Million)
  • Table 11.11: Total Suboxone Film Sales (USD Million)
  • Table 11.12: Suboxone Film: Sales and Market Share in the US (USD Billion)
  • Table 11.13: Prevalence of Alzheimer’s Disease in the US: Distribution by Age
  • Table 11.14: Total Donepezil Hydrochloride Sales (USD Million)
  • Table 11.15: Aricept Sales by Eisai(JPY Billion)
  • Table 11.16: Aricept Sales by Pfizer (USD Million)
  • Table 11.17: Total Fentanyl Sales (USD Million)
  • Table 11.18: Total Fentanyl Citrate Sales (USD Million)
  • Table 11.19: Total Fentanyl Transdermal System Sales (USD Million)
  • Table 11.20: Total Influenza Vaccine Sales (USD Million)
  • Table 11.21: Total Levodopa / Carbidopa Sales (USD Million)
  • Table 11.22: Total Montelukast Sodium Sales (USD Million)
  • Table 11.23: Total Singulair Sales (USD Million)
  • Table 11.24: Total Olanzapine Sales (USD Million)
  • Table 11.25: Total Zyprexa Sales (USD Million)
  • Table 11.26: Total Penicillin G Benzathine Sales (USD Million)
  • Table 11.27: Total Penicillin G Potassium Sales (USD Million)
  • Table 11.28: Total Rizatriptan Benzoate Sales (USD Million)
  • Table 11.29: Total Maxalt Sales (USD Million)
  • Table 11.30: Total Rotavirus Vaccine Sales (USD Million)
  • Table 11.31: Total Zolmitriptan Sales (USD Million)
  • Table 11.32: Total Zomig Sales (USD Million)
  • Table 11.33: Overall Oral Thin Films Market (USD Million), 2015-2025 (Base Scenario)
  • Table 11.34: Overall Oral Thin Films Market (USD Million), 2015-2025 (Conservative Scenario)
  • Table 11.35: Overall Oral Thin Films Market (USD Million), 2015-2025 (Optimistic Scenario)
  • Table 11.36: Suboxone film and Bunavail Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Base Scenario)
  • Table 11.37: Suboxone film and Bunavail Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Conservative Scenario)
  • Table 11.38: Suboxone film and Bunavail Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Optimistic Scenario)
  • Table 11.39: Suboxone film and Bunavail Sales Forecast (USD Million):Long Term, 2020-2025 (Base Scenario)
  • Table 11.40: Suboxone film and Bunavail Sales Forecast (USD Million):Long Term, 2020-2025 (Conservative Scenario)
  • Table 11.41: Suboxone film and Bunavail Sales Forecast (USD Million):Long Term, 2020-2025 (Optimistic Scenario)
  • Table 11.42: Fentanyl Oral Thin Film Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Base Scenario)
  • Table 11.43: Fentanyl Oral Thin Film Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Conservative Scenario)
  • Table 11.44: Fentanyl Oral Thin Film Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Optimistic Scenario)
  • Table 11.45: Fentanyl Oral Thin Film Sales Forecast (USD Million):Long Term, 2020-2025 (Base Scenario)
  • Table 11.46: Fentanyl Oral Thin Film Sales Forecast (USD Million):Long Term, 2020-2025 (Conservative Scenario)
  • Table 11.47: Fentanyl Oral Thin Film Sales Forecast (USD Million):Long Term, 2020-2025 (Optimistic Scenario)
  • Table 11.48: Ondansetron Oral Thin Film Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Base Scenario)
  • Table 11.49: Ondansetron Oral Thin Film Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Conservative Scenario)
  • Table 11.50: Ondansetron Oral Thin Film Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Optimistic Scenario)
  • Table 11.51: Ondansetron Oral Thin Film Sales Forecast (USD Million):Long Term, 2020-2025 (Base Scenario)
  • Table 11.52: Ondansetron Oral Thin Film Sales Forecast (USD Million):Long Term, 2020 -2025 (Conservative Scenario)
  • Table 11.53: Ondansetron Oral Thin Film Sales Forecast (USD Million): Long Term, 2020-2025 (Optimistic Scenario)
  • Table 11.54: Olanzapine RapidFilm Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Base Scenario)
  • Table 11.55: Olanzapine RapidFilm Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Conservative Scenario)
  • Table 11.56: Olanzapine RapidFilm Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Optimistic Scenario)
  • Table 11.57: Olanzapine RapidFilm Sales Forecast (USD Million):Long Term, 2020-2025 (Base Scenario)
  • Table 11.58: Olanzapine RapidFilm Sales Forecast (USD Million):Long Term, 2020-2025 (Conservative Scenario)
  • Table 11.59: Olanzapine RapidFilm Sales Forecast (USD Million):Long Term, 2020-2025 (Optimistic Scenario)
  • Table 11.60: Donepezil RapidFilm Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Base Scenario)
  • Table 11.61: Donepezil RapidFilm Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Conservative Scenario)
  • Table 11.62: Donepezil RapidFilm Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Optimistic Scenario)
  • Table 11.63: Donepezil RapidFilm Sales Forecast (USD Million): Long Term, 2020-2025 (Base Scenario)
  • Table 11.64: Donepezil RapidFilm Sales Forecast (USD Million): Long Term, 2020-2025 (Conservative Scenario)
  • Table 11.65: Donepezil RapidFilm Sales Forecast (USD Million): Long Term, 2020-2025 (Optimistic Scenario)
  • Table 11.66: Zolmitriptan RapidFilm Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Base Scenario)
  • Table 11.67: Zolmitriptan RapidFilm Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Conservative Scenario)
  • Table 11.68: Zolmitriptan RapidFilm Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Optimistic Scenario)
  • Table 11.69: Zolmitriptan RapidFilm Sales Forecast (USD Million):Long Term, 2020-2025 (Base Scenario)
  • Table 11.70: Zolmitriptan RapidFilm Sales Forecast (USD Million):LongTerm, 2020-2025 (Conservative Scenario)
  • Table 11.71: Zolmitriptan RapidFilm Sales Forecast (USD Million):Long Term, 2020-2025 (Optimistic Scenario)
  • Table 11.72: Rizaport Sales Forecast (USD Million): Short-Mid Term 2016-2020 (Base Scenario)
  • Table 11.73: Rizaport Sales Forecast (USD Million): Short-Mid Term 2016-2020 (Conservative Scenario)
  • Table 11.74: Rizaport Sales Forecast (USD Million): Short-Mid Term 2016-2020 (Optimistic Scenario)
  • Table 11.75: Rizaport Sales Forecast (USD Million): Long Term, 2020-2025 (Base Scenario)
  • Table 11.76: Rizaport Sales Forecast (USD Million): Long Term, 2020-2025 (Conservative Scenario)
  • Table 11.77: Rizaport Sales Forecast (USD Million): Long Term, 2020-2025 (Optimistic Scenario)
  • Table 11.78: BEMA Buprenorphine Sales Forecast (USD Million): Short-Mid Term 2016-2020 (Base Scenario)
  • Table 11.79: BEMA Buprenorphine Sales Forecast (USD Million): Short-Mid Term 2016-2020 (Conservative Scenario)
  • Table 11.80: BEMA Buprenorphine Sales Forecast (USD Million): Short-Mid Term 2016-2020 (Optimistic Scenario)
  • Table 11.81: BEMA Buprenorphine Sales Forecast (USD Million):Long Term, 2020-2025 (Base Scenario)
  • Table 11.82: BEMA Buprenorphine Sales Forecast (USD Million):Long Term, 2020-2025 (Conservative Scenario)
  • Table 11.83: BEMA Buprenorphine Sales Forecast (USD Million):Long Term, 2020-2025 (Optimistic Scenario)
  • Table 11.84: Montelukast Sodium PharmFilm Sales Forecast (USD Million): Short-Mid Term 2016-2020 (Base Scenario)
  • Table 11.85: Montelukast Sodium PharmFilm Sales Forecast (USD Million): Short-Mid Term 2016-2020 (Conservative Scenario)
  • Table 11.86: Montelukast Sodium PharmFilm Sales Forecast (USD Million): Short-Mid Term 2016-2020 (Optimistic Scenario)
  • Table 11.87: Montelukast Sodium PharmFilm Sales Forecast (USD Million):Long Term, 2020-2025 (Base Scenario)
  • Table 11.88: Montelukast Sodium PharmFilm Sales Forecast (USD Million):Long Term, 2020-2025 (Conservative Scenario)
  • Table 11.89: Montelukast Sodium PharmFilm Sales Forecast (USD Million):Long Term, 2020-2025 (Optimistic Scenario)
  • Table 11.90: IntelGenX Revenues, 2007-2013(USD Million)
  • Table 11.91: BioDelivery Sciences Revenues, 2009-2013 (USD Million)

List of Companies:

The following companies and organizations have been mentioned in the report.

  • 1. Aavishkar
  • 2. Abdi Ibrahim Pharmaceuticals
  • 3. Actavis
  • 4. Actavis Pharma
  • 5. Adagio Pharmaceuticals
  • 6. Adhesives Research
  • 7. ALK Lifeline
  • 8. Amcor Flexibles
  • 9. Apotek Produktion and Laboratorier
  • 10. ApotheekZorg
  • 11. Applied Pharma Research
  • 12. Archimedes
  • 13. Arcion Therapeutics
  • 14. Aridis Pharmaceuticals
  • 15. AstraZeneca
  • 16. Aurobindo Pharma
  • 17. Aveva Drug Delivery Systems
  • 18. Baxter Healthcare
  • 19. Bharat Biotech
  • 20. BioAlliance Pharma
  • 21. BioDelivery Sciences
  • 22. BioFilm
  • 23. BiondVax Pharmaceuticals
  • 24. Bristol-Myers Squibb
  • 25. Buccal Pharma
  • 26. C.L Pharm
  • 27. Cadila Pharmaceuticals
  • 28. Cipla
  • 29. Clonmel Healthcare
  • 30. Cure Pharmaceuticals
  • 31. Cynapsus Therapeutics
  • 32. Dr. Reddy’s Laboratories
  • 33. Edgemont Pharmaceuticals
  • 34. Eisai
  • 35. Eli Lilly
  • 36. Endo Pharmaceuticals
  • 37. Engineered Production Equipment
  • 38. Ethypharm
  • 39. Ferrer Internacional
  • 40. FFT Medical
  • 41. Galena Biopharma
  • 42. Galenix Innovations
  • 43. Gammatec
  • 44. Gen Ilac
  • 45. Genus Pharmaceuticals
  • 46. GlaxoSmithKline
  • 47. Hikma Pharmaceuticals
  • 48. Hilleman Laboratories
  • 49. Hospira
  • 50. Huahai US
  • 51. Impax Pharmaceuticals
  • 52. Innoteq
  • 53. InnoZen
  • 54. Insys Therapeutics
  • 55. IntelGenX
  • 56. Italfarmaco
  • 57. ITF Hellas
  • 58. J-Pac Medical
  • 59. Jubilant Generics
  • 60. Jubilant Life Sciences
  • 61. KemPharm
  • 62. Kunwha Pharmaceutical Co. Ltd
  • 63. Laboratoire Aguettant
  • 64. LaviPharm
  • 65. Licher MT
  • 66. Lincoln Medical
  • 67. LTS Lohmann Therapie-Systeme AG
  • 68. Macleods Pharmaceuticals
  • 69. Macular Health
  • 70. Matrix Laboratories
  • 71. Meda A.B
  • 72. Meda Pharmaceuticals
  • 73. Meda Valeant Pharma Canada Inc.
  • 74. Merck
  • 75. MidaSol Therapeutics
  • 76. MonoSol Rx
  • 77. Mylan Pharmaceuticals
  • 78. NAL Pharma
  • 79. NeuroHealing Pharmaceuticals
  • 80. NordicInfu Care
  • 81. Norgine
  • 82. Novartis
  • 83. ODF Pharma
  • 84. Orexo AB
  • 85. Otsuka Pharmaceuticals
  • 86. Pace Wellness
  • 87. Par Pharmaceutical
  • 88. Pediology
  • 89. Pfizer
  • 90. Pliva Hrvatska
  • 91. Quintiles
  • 92. Ranbaxy
  • 93. Reckitt Benckiser Pharmaceuticals
  • 94. RedHill Biopharma
  • 95. Renantos Pharmavertriebsges. mbH
  • 96. Roxane-
  • 97. Sandoz
  • 98. Sanofi Pasteur
  • 99. Sato Pharmaceuticals
  • 100. SciClone Pharmaceuticals
  • 101. Sciele Pharma
  • 102. Sharp Packaging Services
  • 103. Stada Asia
  • 104. Strativa Pharmaceuticals
  • 105. Sun Pharmaceutical
  • 106. Takeda
  • 107. tesa Labtec GmbH
  • 108. Teva Pharmaceuticals
  • 109. Torrent Pharmaceuticals
  • 110. TTY Biopharm
  • 111. US WorldMeds
  • 112. Vestiq Holdings
  • 113. Wansar Corporation
  • 114. Wockhardt
  • 115. Wyeth
  • 116. Zengen
  • 117. Zydus
Back to Top